1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €44.63 (+5.11%). The median is €45.61 (+7.42%).
| Buy |
3 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -84.99K | - |
| Net profit | -45.22M | 947.33% |
| EBITDA | -47.16M | 965.48% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.17B |
Number of shares | 28.68M |
52-week high/low | €43.17 - €11.50 |
| Dividends | No |
Beta | 0.42 |
P/E ratio | -16.00 |
PEG ratio | -0.09 |
P/B ratio | 4.31 |
P/S ratio | 0.00 |
Company profile
Biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapien für neuropsychiatrische Erkrankungen (z. B. Schizophrenie, bipolare Depression) entwickelt. Hauptkandidat ist LB-102, ein methyliertes Derivat von Amisulprid.
| Name | LB Pharmaceuticals |
| CEO | Heather D. Turner |
| Website | |
| IPO | 09/11/2025 |
| Employees | 49 |
Deep Dive
Discover assets
Shareholders of LB Pharmaceuticals also invest in the following assets
